Senju Pharmaceutical Co., Ltd.
http://www.senju.co.jp
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Senju Pharmaceutical Co., Ltd.
Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results
The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.
Breakthrough Designation Binge In February By US FDA Didn’t Extend To Approvals
Six new breakthrough therapy designations have been announced, all for novel agents, but approvals were fewer and limited to new indications and formulations.
Finance Watch: More Good To Come? CG Oncology Grosses $380m In Year’s First IPO
Public Company Edition: CG Oncology grossed $380m in the first biopharma IPO in the US in 2024. Follow-on offerings have been robust recently, with Edgewise and Immatics grossing $240m and $175m, respectively.
US FDA’s Missed User Fee Goals Spiked In 2023 – And Not Just Because Of COVID-19
CDER missed six goal dates among its 2023 novel approvals, reflecting safety concerns as well as pandemic-related inspection delays; Duchenne muscular dystrophy accelerated approval disagreements caused the biologics center’s lone missed goal.
Company Information
- Industry
- Diversified
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Senju USA Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice